We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+20.38%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$350M
AUM Growth
+$37.4M
Cap. Flow
-$13.1M
Cap. Flow %
-3.75%
Top 10 Hldgs %
66.13%
Holding
48
New
13
Increased
10
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$9.24M
2
OCUL icon
Ocular Therapeutix
OCUL
+$6.25M
3
ASRT
Assertio
ASRT
+$4.38M
4
PTCT icon
PTC Therapeutics
PTCT
+$3.67M
5
TGTX icon
TG Therapeutics
TGTX
+$3.5M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$16.4M
2
IMMU
Immunomedics Inc
IMMU
+$14.5M
3
BPMC
Blueprint Medicines
BPMC
+$11.6M
4
AXGN icon
Axogen
AXGN
+$7.82M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$6.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.61%
2 Miscellaneous 6.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
26
Syndax Pharmaceuticals
SNDX
$1.8B
$3.17M 0.91%
+222,500
New +$2.36M
CMRX
27
DELISTED
Chimerix, Inc.
CMRX
$3.12M 0.89%
600,000
– –
QTRX icon
28
Quanterix
QTRX
$125M
$2.56M 0.73%
150,000
+85,000
+131% +$1.7M
PLX icon
29
Protalix BioTherapeutics
PLX
$210M
$1.76M 0.5%
326,000
+143,500
+79% +$944K
FBIO icon
30
Fortress Biotech
FBIO
$93.4M
$1.43M 0.41%
+21,000
New +$1.33M
EPZM
31
DELISTED
Epizyme, Inc
EPZM
$1.24M 0.36%
+70,000
New +$1.18M
SYRS
32
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$961K 0.27%
7,407
– –
ZSAN
33
DELISTED
Zosano Pharma Corporation
ZSAN
$504K 0.14%
+2,857
New +$956K
QTNT
34
DELISTED
Quotient Limited Ordinary Shares
QTNT
$282K 0.08%
+1,500
New +$271K
BLRX
35
BioLineRX
BLRX
$12.1M
$214K 0.06%
417
– –
ARGX icon
36
argenx
ARGX
$66.2B
– –
-88,500
Closed -$5.59M
CRSP icon
37
CRISPR Therapeutics
CRSP
$5.74B
– –
-281,000
Closed -$6.6M
NKTR icon
38
Nektar Therapeutics
NKTR
$2.55B
– –
-5,333
Closed -$4.78M
QURE icon
39
uniQure
QURE
$3.44B
– –
-90,801
Closed -$1.78M
RCKT icon
40
Rocket Pharmaceuticals
RCKT
$397M
– –
-450,500
Closed -$4.7M
RYTM icon
41
Rhythm Pharmaceuticals
RYTM
$7.75B
– –
-38,300
Closed -$1.11M
SPPI
42
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-31,000
Closed -$587K
XLRN
43
DELISTED
Acceleron Pharma
XLRN
– –
-101,500
Closed -$4.31M
IMMU
44
DELISTED
Immunomedics Inc
IMMU
– –
-898,800
Closed -$14.5M
DERM
45
DELISTED
Dermira, Inc.
DERM
– –
-100,000
Closed -$2.78M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2018 Portfolio in Review

As of Q1 2018, Opaleye Management held 48 positions worth $350M, up 12% from $312M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Opaleye Management withdrew a net $13.1M in Q1 2018, closing 10 positions and reducing 7 holdings. Its most notable exit was Immunomedics Inc, an estimated $14.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Deciphera Pharmaceuticals, Inc. Common Stock worth $7.31M.

  • Opaleye Management's largest Q1 2018 buy was Deciphera Pharmaceuticals, Inc. Common Stock: 365,000 shares worth $7.31M.
  • Opaleye Management added most to Viking Therapeutics in Q1 2018, an estimated $3.43M increase.
  • Opaleye Management's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $16.4M.
  • Opaleye Management fully exited Immunomedics Inc in Q1 2018, selling an estimated $14.5M.
  • Opaleye Management's ten largest holdings make up 66% of its $350M portfolio in Q1 2018.
  • Opaleye Management opened 13 new positions and closed 10 in Q1 2018.
  • Opaleye Management's portfolio value rose 12% quarter-over-quarter to $350M.

Based on Opaleye Management's 13F filing for Q1 2018, filed 14 May 2018.